Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/33281
Type
ArticleCopyright
Open access
Collections
- ENSP - Artigos de Periódicos [2363]
- IOC - Artigos de Periódicos [12841]
Metadata
Show full item record
NO DIFFERENCE IN LEPROSY TREATMENT OUTCOMES COMPARING 12- AND 24-DOSE MULTIDRUG REGIMENS: A PRELIMINARY STUDY
Alternative title
Nenhuma diferença na evolução da hanseníase entre os esquemas terapêuticos de 12 versus 24 doses: um estudo preliminarAuthor
Affilliation
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Escola Nacional de Saúde Pública Sergio Arouca. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Rio de Janeiro, RJ, Brasil.
Abstract
A comparative study was performed on the initial and final bacillary indexes of 213 multibacillary leprosy patients who received 12 doses
(Group 1: 128 patients) or 24 doses (Group 2: 85 patients) of multidrug therapy (MDT/WHO) to measure the effectiveness of the two regimens.
All patients were evaluated at treatment baseline, 12 months, and 24 months. The reduction in bacillary levels and mean bacillary indexes
at 24 months was similar in the two groups. No statistical difference in reaction rates was observed between the two treatment regimens.
Share